Annalise.ai, a prominent global player in the radiology imaging sector, has unveiled a groundbreaking solution tailored specifically for the U.S. market – Annalise Triage. This innovative software is set to reshape the landscape of radiology by providing radiologists with a powerful tool to efficiently triage studies, prioritize cases with suspected critical findings, streamline workflows, and ultimately accelerate the time-to-diagnosis for urgent conditions.
Key Features and FDA Clearance:
Annalise Triage comes equipped with an impressive array of 12 FDA-cleared findings, comprising five for chest X-ray (CXR) and seven for non-contrast head CT (CTB). Notably, this comprehensive offering received the coveted 510(k) clearance and breakthrough designation for obstructive hydrocephalus, making it the exclusive radiology triage device to achieve such recognition. This designation is reserved for devices that fulfill specific criteria, including enhancing the diagnosis or treatment of life-threatening conditions, offering breakthrough technology, presenting a significant advantage over existing alternatives, and being in the best interest of patients.
Critical Findings and Diagnostic Capabilities:
By implementing Annalise Triage, radiologists gain the ability to swiftly and accurately detect a range of critical, time-sensitive conditions from unenhanced head CT studies. These conditions include acute subdural hematoma, acute subarachnoid hemorrhage, intra-axial hemorrhage, intraventricular hemorrhage, obstructive hydrocephalus, mass effect, and vasogenic edema. Additionally, the software facilitates the identification of critical findings on chest X-rays, such as pleural effusion, pneumoperitoneum, vertebral compression fracture, pneumothorax, and tension pneumothorax.
Addressing Industry Challenges:
In the face of growing imaging backlogs and radiology workforce shortages, Annalise Triage strategically addresses the pressing need to enhance workflow efficiency in U.S. radiology. Worklist prioritization has emerged as a crucial use case for AI in radiology, and Annalise.ai stands at the forefront of this transformative trend. Recognizing the industry challenges, the company expedited regulatory approvals, becoming one of the fastest AI providers to achieve 12 findings cleared by the FDA in under two years.
Testimonial from Chief Medical Officer:
Dr. Rick Abramson, Chief Medical Officer at Annalise.ai, emphasized the advanced algorithms’ role in supporting radiologists by facilitating the prioritization of studies with suspected critical findings. This, in turn, optimizes radiology workflow, promoting faster report turnaround times by identifying and elevating critical cases for immediate attention.
Strengths and Commitment to Innovation:
One of Annalise’s key strengths in the U.S. radiology triage market lies in the breadth and depth of its triage findings. Annalise Triage offers the most extensive radiology triage portfolio available in the United States for chest X-ray and un-enhanced head CT. This aligns seamlessly with the company’s track record of providing one of the most comprehensive diagnostic support portfolios worldwide. Powered by one of the world’s largest and most diverse datasets, Annalise.ai algorithms are trained using input from a pool of over 140 fully qualified consulting radiologists.
Annalise Triage stands as a testament to Annalise.ai’s commitment to innovation and dedication to improving patient care. This cutting-edge technology, with its worklist prioritization capabilities, is poised to redefine the radiology triage landscape in the United States. By empowering healthcare professionals with advanced tools, Annalise.ai aims to improve patient outcomes and contribute to the ongoing advancements in the field of radiology.
